Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

ConclusionsDespite consistent guideline recommendations for cytoreductive therapy in patients with high-risk PV, this analysis revealed that only a minority of these patients received cytoreductive medication. A notable proportion of high-risk patients with PV would likely benefit from a revised treatment plan that aligns with current guidelines.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research